Small molecule inducers of trained immunity found
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
List view / Grid view
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
In an animal model, scientists have demonstrated that targeting Interleukin-10 during vaccine delivery enhances the vaccine’s ability to protect against infection.
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
A new assay has been developed which enables the detailing of intact proviral genomes of under-studied HIV strains.
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
In animal studies, the new vaccine construct outperformed another PNAG-vaccine delivery system currently in human trials.
The vaccine provided complete protection with no detectable virus in the lungs and could be a routine part of people’s medical treatment.
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
A lab generated monoclonal antibody prevented EBV infection and EBV lymphomas in rodent models and could have future clinical applications.
A new study shows that changes in clonal dominance characterises T-cell memory against multiple COVID-19 variants following mRNA vaccinations.
The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
Researchers found that the D48 antibody neutralised HSV-1 virus infection, which could lead to broad-spectrum drug and vaccine development.
A new vaccine, based on a nanoliposome that promotes proteins to be displayed on its surface, results in potent vaccine efficacy.